Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4A | P47712 | 2/20 | 0.57 |
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | PLA2G4C | Q9UP65 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 3/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893644 | 1.00 | PLA2G4A (0.57) | PLA2G4AFAAHALDH1A1MAPTBLM | |
| SCHEMBL5324851 | 0.96 | PLA2G4A (0.62) | PLA2G4AFAAHALDH1A1MAPTBLM | |
| SCHEMBL28417663 | 0.91 | FAAH (0.53) | PLA2G4AFAAHALDH1A1MAPTBLM | |
| SCHEMBL24938544 | 0.91 | FAAH (0.53) | PLA2G4AFAAHALDH1A1MAPTBLM | |
| SCHEMBL1428312 | 0.85 | FAAH (0.41) | PLA2G4AFAAHALDH1A1MAPTBLM | |
| SCHEMBL1818263 | 0.85 | FAAH (0.50) | PLA2G4AFAAHALDH1A1MAPTBLM | |
| SCHEMBL1818265 | 0.85 | FAAH (0.50) | PLA2G4AFAAHALDH1A1MAPTBLM | |
| SCHEMBL1428313 | 0.82 | FAAH (0.47) | PLA2G4AFAAHALDH1A1MAPTBLM | |
| SCHEMBL1428310 | 0.82 | FAAH (0.47) | PLA2G4AFAAHALDH1A1MAPTBLM | |
| SCHEMBL19572670 | 0.82 | TRPV1 (0.73) | FAAHALDH1A1MAPTBLMTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665739-A1 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2013-11-27 | — | — | EP | claimed |
| WO-2012100248-A1 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2012-07-26 | — | — | WO | claimed |
| US-20120114670-A1 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | UNIVERSITY OF ROCHESTER (US) | 2012-05-10 | — | — | US | claimed |
| US-20120082659-A1 | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-04-05 | — | — | US | claimed |
| US-20100285001-A1 | Method and Compositions Related to Synergistic Responses to Oncogenic Mutations | UNIVERSITY OF ROCHESTER (US) | 2010-11-11 | — | — | US | claimed |
| EP-2188630-A2 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2010-05-26 | — | — | EP | claimed |
| WO-2009045443-A2 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2009-04-09 | — | — | WO | claimed |
| US-10870885-B2 | Dendritic cell response gene expression, compositions of matters and methods of use thereof | THE BROAD INSTITUTE, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| EP-2971116-A1 | DENDRITIC CELL RESPONSE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | The Broad Institute, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150368719-A1 | DENDRITIC CELL RESPONSE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2015-12-24 | — | — | US | disclosed |
| WO-2014145631-A1 | DENDRITIC CELL RESPONSE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2665739-A1 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2013-11-27 | — | — | EP | disclosed |
| US-20130184223-A1 | METHODS AND COMPOSITIONS RELATED TO MODULATING AUTOPHAGY | UNIVERSITY OF ROCHESTER (US) | 2013-07-18 | — | — | US | disclosed |
| US-20110263693-A1 | CELASTROL, GEDUNIN, AND DERIVATIVES THEREOF AS HSP90 INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110150775-A1 | GENOMIC APPROACHES TO FETAL TREATMENT AND DIAGNOSIS | TUFTS MEDICAL CENTER, INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110045998-A1 | CANDIDATE GENES AND BLOOD BIOMARKERS FOR BIPOLAR MOOD DISORDER, ALCOHOLISM AND STRESS DISORDER | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-02-24 | — | — | US | disclosed |
| US-20100285001-A1 | Method and Compositions Related to Synergistic Responses to Oncogenic Mutations | UNIVERSITY OF ROCHESTER (US) | 2010-11-11 | — | — | US | disclosed |
| EP-2188630-A2 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009045443-A2 | METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC RESPONSES TO ONCOGENIC MUTATIONS | THE UNIVERSITY OF ROCHESTER (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2007117466-A2 | CELASTROL, GEDUNIN, AND DERIVATIVES THEREOF AS HSP90 INHIBITORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263693-A1 | CELASTROL, GEDUNIN, AND DERIVATIVES THEREOF AS HSP90 INHIBITORS | HSP90AA1, HSP90AB1, HSP90AB2P | PLA2G4A 3953/4885FAAH 4066/4885ALDH1A1 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.